clinical trials

News

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.

News

Another clinical trial setback disappoints the ALS patient community, this time involving Denali's eIF2B agonist DNL343.

R&D

Drug development is a high-stakes, high-cost endeavour.

News

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

News

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.

News

Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug.